Bionano Genomics Inc. [NASDAQ: BNGO] traded at a high on 09/17/20, posting a 6.76 gain after which it closed the day’ session at $0.63. The company report on September 17, 2020 that Bionano Data Provides Understanding of Repeat Expansion Disorders Causing Muscular Dystrophy and ALS.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that teams from the Mayo Clinic and from the University of Florida have separately released results generated with Saphyr relating to Amyotrophic Lateral Sclerosis (ALS) and Myotonic Dystrophy (DM), respectively, two severe genetic disorders caused by the expansion of repetitive sequences in the genome. Saphyr identified repeat expansions in patients with ALS and DM that were so large that only Saphyr is capable of sizing them correctly. These findings help increase understanding of the disease-causing mechanisms and may lead to better diagnostic tests, support direct drug development and facilitate better identification of patients who are likely to respond to treatment.
In a study published in bioRxiv, a team led by Dr. Eric Wang from the University of Florida used Saphyr to identify genomic variants that determine the severity of neurological symptoms caused by DM. These symptoms, caused by an abnormal processing of a number of brain-expressed genes, correlate with the length of a repeat expansion. The study helped demonstrate that ultra-long DNA analysis technology, such as Bionano’s Saphyr, is crucial to enabling the accurate measurement of these repeat expansions.
The results of the trading session contributed to over 10854159 shares changing hands. Over the past one week, the price volatility of Bionano Genomics Inc. stands at 9.59% while the volatility over the past one month is 9.43%.
The market cap for BNGO stock reached $90.66 million, with 144.65 million shares outstanding and 136.15 million shares in the current float. Compared to the average trading volume of 22.99M shares, BNGO reached a trading volume of 10854159 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bionano Genomics Inc. [BNGO]?
Oppenheimer have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 08, 2020.
The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.06, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 10.79. The Price to Book ratio for the last quarter was 10.50, with the Price to Cash per share for the same quarter was set at 0.12.
How has BNGO stock performed recently?
Bionano Genomics Inc. [BNGO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.32. With this latest performance, BNGO shares dropped by -12.28% in over the last four-week period, additionally plugging by 57.50% over the last 6 months – not to mention a drop of -40.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 50.68, with the RSI for the last a single of trading hit 58.33, and the three-weeks RSI is set at 51.00 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 0.6676, while it was recorded at 0.5771 for the last single week of trading, and 0.7080 for the last 200 days.
Bionano Genomics Inc. [BNGO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -255.44 and a Gross Margin at +22.46. Bionano Genomics Inc.’s Net Margin is presently recorded at -294.34.
Return on Total Capital for BNGO is now -120.73, given the latest momentum, and Return on Invested Capital for the company is -261.76. Return on Equity for this stock declined to -433.64, with Return on Assets sitting at -108.40. When it comes to the capital structure of this company, Bionano Genomics Inc. [BNGO] has a Total Debt to Total Equity ratio set at 555.80. Additionally, BNGO Total Debt to Total Capital is recorded at 84.75, with Total Debt to Total Assets ending up at 66.49.
Reflecting on the efficiency of the workforce at the company, Bionano Genomics Inc. [BNGO] managed to generate an average of -$307,372 per employee. Receivables Turnover for the company is 1.87 with a Total Asset Turnover recorded at a value of 0.37.Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.
Earnings analysis for Bionano Genomics Inc. [BNGO]
With the latest financial reports released by the company, Bionano Genomics Inc. posted -0.59/share EPS, while the average EPS was predicted by analysts to be reported at -0.45/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -31.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BNGO.
Insider trade positions for Bionano Genomics Inc. [BNGO]
There are presently around $2 million, or 3.50% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: SIO CAPITAL MANAGEMENT, LLC with ownership of 1,546,184, which is approximately New of the company’s market cap and around 10.41% of the total institutional ownership; BANK JULIUS BAER & CO. LTD, ZURICH, holding 749,998 shares of the stock with an approximate value of $0.47 million in BNGO stocks shares; and VANGUARD GROUP INC, currently with $0.22 million in BNGO stock with ownership of nearly 76.177% of the company’s market capitalization.
Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 18 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 2,838,938 shares. Additionally, 5 investors decreased positions by around 1,252,706 shares, while 3 investors held positions by with 219,815 shares. The mentioned changes placed institutional holdings at 3,871,829 shares, according to the latest SEC report filing. BNGO stock had 11 new institutional investments in for a total of 2,122,251 shares, while 4 institutional investors sold positions of 1,252,705 shares during the same period.